12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anti-TWEAK: Phase II started

Biogen Idec disclosed in its 3Q12 earnings that during the quarter it began the double-blind, placebo-controlled, international Phase II ATLAS trial to evaluate low- and high-dose IV BIIB023 in combination with background therapy, including oral steroids...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >